Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

High-Intensity Interval Versus Aerobic Training for Patient-Reported Outcomes in Women With Heart Failure. (HIIT-WHEF)

3 novembre 2026 mis à jour par: Universidad Internacional Isabel I de Castilla

Entrenamiento interválico de Alta Intensidad Versus Entrenamiento aeróbico Para Resultados Reportados Por Pacientes en Mujeres Con Insuficiencia cardíaca (HIIT-WHEF, High-intensity Interval Versus Aerobic Training for Patient-reported Outcomes in Women With Heart Failure): un Ensayo clínico Piloto, Prospectivo, Aleatorizado y de Factibilidad.

Heart failure is associated with impaired health-related quality of life and reduced exercise capacity. Women remain under-represented in cardiac rehabilitation research, and evidence comparing high-intensity interval training (HIIT) with moderate-intensity continuous training (MICT) in women with heart failure is limited.

HIIT-WHEF is a prospective, single-centre, randomised pilot feasibility trial involving 36 women aged 18 years or older with heart failure and a left ventricular ejection fraction below 50%. Participants will be randomly allocated in a 1:1 ratio to a 12-week supervised cardiac rehabilitation programme incorporating either HIIT or MICT. Both groups will also undertake individualised resistance training.

The primary objectives are to assess the feasibility and safety of conducting the randomised trial, including recruitment, acceptance, retention, adherence, intervention fidelity, completeness of outcome data and exercise-related adverse events. Health-related quality of life, assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ), is the key clinical outcome of interest. Peak oxygen uptake, left ventricular ejection fraction and biomarkers will be assessed as exploratory clinical outcomes.

The study is designed to inform the planning of a future adequately powered confirmatory trial. It is not intended to establish definitive evidence of the superiority of HIIT over MICT.

Aperçu de l'étude

Description détaillée

HIIT-WHEF will be conducted in the cardiac rehabilitation unit of Hospital Universitario Reina Sofía, Córdoba, Spain. Eligible women with clinically stable heart failure, New York Heart Association functional class I-II, a left ventricular ejection fraction below 50%, and stable, guideline-directed medical treatment will be considered for participation following referral for cardiac rehabilitation.

After baseline assessment and written informed consent, 36 participants will be randomly allocated to HIIT or MICT in a 1:1 ratio, with concealed allocation. Outcome assessors and data analysts will remain blinded to treatment allocation where feasible.

Both interventions will be delivered over 12 weeks, three supervised sessions per week. HIIT will comprise repeated high-intensity exercise intervals above the second ventilatory threshold, interspersed with active recovery below the first ventilatory threshold. MICT will comprise continuous aerobic exercise at an individually prescribed moderate intensity, between the first and second ventilatory thresholds. Both groups will receive resistance training, with exercise prescription and progression individualised according to functional capacity, symptoms and clinical response.

Feasibility outcomes will include recruitment rate, acceptance of randomisation, retention, adherence to prescribed sessions, fidelity to the assigned intervention, completeness of MLHFQ and other outcome assessments, and the frequency and nature of adverse events, particularly those related to exercise.

The MLHFQ will be assessed before and after the intervention. Peak oxygen uptake will be measured by cardiopulmonary exercise testing, left ventricular ejection fraction by echocardiography, and relevant blood biomarkers will be collected. Clinical outcomes will be analysed primarily using analysis of covariance, adjusting for baseline values, and reported with estimates and 95% confidence intervals. Given the pilot design and sample size, clinical comparisons will be exploratory and will inform the design of a future confirmatory trial.

Women who decline cardiac rehabilitation may be invited to participate in a separate observational registry, subject to separate informed consent. These women will not form part of the randomised comparison.

Type d'étude

Interventionnel

Inscription (Estimé)

36

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Córdoba
      • Córdoba, Córdoba, Espagne, 14005
        • Hospital Universitario Reina Sofía.

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  1. Women aged 18 years or older.
  2. Documented diagnosis of heart failure with a left ventricular ejection fraction (LVEF) below 50%.
  3. Stable symptoms corresponding to New York Heart Association functional class I-II.
  4. Clinically stable and receiving stable, guideline-directed medical treatment at the maximum tolerated doses, as appropriate.
  5. Referred by the responsible cardiologist for cardiac rehabilitation according to usual clinical practice.
  6. No contraindication to supervised cardiac rehabilitation, cardiopulmonary exercise testing or the allocated exercise intervention.
  7. Written informed consent provided before enrolment.

Exclusion Criteria:

  1. Acute coronary syndrome or cardiac surgery within the previous 15 days.
  2. Uncontrolled arrhythmias.
  3. Severe valvular heart disease with an indication for intervention.
  4. Musculoskeletal or neurological limitations that prevent the performance of exercise.
  5. Any contraindication to cardiopulmonary exercise testing or high-intensity exercise training.
  6. Clinical or haemodynamic instability, decompensated heart failure, unstable angina, clinically significant uncontrolled arrhythmias, or any other cardiovascular or non-cardiovascular condition that, in the judgement of the responsible clinical team, makes exercise unsafe at the time of assessment.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: High-Intensity Interval Training (HIIT)

Patients assigned to HIIT

A 12-week supervised cardiac rehabilitation programme consisting of three individual sessions per week. Aerobic exercise will be performed on a treadmill or cycle ergometer, with intensity individually prescribed according to cardiopulmonary exercise testing and ventilatory thresholds. Sessions will include a 5-minute warm-up below the first ventilatory threshold, at least four high-intensity intervals above the second ventilatory threshold interspersed with active recovery intervals of equal duration below the first ventilatory threshold, and a 5-minute cool-down. Exercise duration and intensity will be progressed according to individual tolerance and clinical response. Both groups will also undertake individualised resistance training targeting the major muscle groups. Total session duration will be approximately 60 minutes. All sessions will be supervised by a physiotherapist, with clinical monitoring and exercise modification or interruption when indicated for safety.

Comparateur actif: Moderate-Intensity Continuous Training (MICT)

Patients assigned to MICT

A 12-week supervised cardiac rehabilitation programme consisting of three individual sessions per week. Aerobic exercise will be performed on a treadmill or cycle ergometer at an individually prescribed moderate intensity between the first and second ventilatory thresholds, avoiding significant dyspnoea. Sessions will include a 5-minute warm-up below the first ventilatory threshold and a 5-minute cool-down. Exercise duration will progress according to individual tolerance and clinical response, towards approximately 30 minutes of continuous aerobic exercise. Both groups will also undertake individualised resistance training targeting the major muscle groups, progressing towards approximately 40-60% of one-repetition maximum, with 8-15 repetitions and at least two sets per muscle group when tolerated. Total session duration will be approximately 60 minutes. All sessions will be supervised by a physiotherapist, with clinical monitoring and exercise modification or interruption when indic

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Recruitment Rate
Délai: From the start of recruitment to the end of the first 9 months of recruitment.

Number of participants randomised per month during the first nine months of recruitment. Feasibility will be classified as green if at least 2 participants per month are randomised, amber if 1 to less than 2 participants per month are randomised, and red if fewer than 1 participant per month is randomised.

From the start of recruitment to the end of the first 9 months of recruitment.
Acceptance of Randomisation
Délai: From screening and referral throughout the recruitment period.

Proportion of eligible women referred for cardiac rehabilitation who agree to randomisation. Green: at least 50%; amber: 30% to less than 50%; red: less than 30%.

From screening and referral throughout the recruitment period.
Participant Retention
Délai: At the end of the 12-week intervention.

Proportion of randomised participants with a post-intervention assessment. Green: at least 85%; amber: 70% to less than 85%; red: less than 70%.

At the end of the 12-week intervention.
Adherence to Prescribed Exercise Sessions
Délai: Throughout the 12-week intervention.

Proportion of prescribed exercise sessions attended by participants who complete the programme. Green: at least 80%; amber: 65% to less than 80%; red: less than 65%.

Throughout the 12-week intervention.
Fidelity to the Assigned HIIT Intervention
Délai: Throughout the 12-week intervention.

Proportion of HIIT sessions in which at least four intervals are completed above the second ventilatory threshold. Green: at least 75%; amber: 60% to less than 75%; red: less than 60%.

Throughout the 12-week intervention.
Completeness of Post-Intervention MLHFQ Data
Délai: At the end of the 12-week intervention.

Proportion of randomised participants with a completed Minnesota Living with Heart Failure Questionnaire (MLHFQ) at post-intervention assessment. Green: at least 90%; amber: 75% to less than 90%; red: less than 75%.

At the end of the 12-week intervention.
Exercise-Related Adverse Events
Délai: Throughout the 12-week intervention and the study period in which exercise-related adverse events are monitored.

Frequency and nature of adverse events related to exercise, including serious adverse events and events requiring modification of exercise prescription. Feasibility criteria are green if no serious exercise-related adverse event occurs; amber if non-serious events require modification of the prescription in more than 20% of cases; and red if any serious adverse event attributable to exercise occurs.

Throughout the 12-week intervention and the study period in which exercise-related adverse events are monitored.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Total Score
Délai: Baseline and 12 weeks.

Between-group difference in the post-intervention MLHFQ total score, adjusted for baseline score using analysis of covariance (ANCOVA). The MLHFQ ranges from 0 to 105, with higher scores indicating worse health-related quality of life. The baseline-to-post-intervention change will also be reported. This is an exploratory clinical outcome in the pilot trial and will not be used to establish confirmatory superiority.

Baseline and 12 weeks.
Change in Peak Oxygen Consumption (VO2peak)
Délai: Baseline and at 12 weeks

Between-group difference in peak oxygen uptake measured during cardiopulmonary exercise testing, adjusted for baseline VO2peak. VO2peak will be expressed in mL/kg/min and defined as the highest oxygen uptake achieved during the final 30 seconds of exercise.

Baseline and at 12 weeks
Change in Left Ventricular Ejection Fraction (LVEF)
Délai: Baseline and at 12 weeks

Between-group difference in left ventricular ejection fraction measured by echocardiography, adjusted for baseline LVEF. Results will be expressed as percentage points.

Baseline and at 12 weeks
Changes in NT-proBNP, High-Sensitivity C-Reactive Protein and CA125
Délai: Baseline and at 12 weeks

Changes in circulating NT-proBNP, high-sensitivity C-reactive protein (hs-CRP) and CA125 concentrations from baseline to post-intervention. Between-group comparisons will be exploratory and adjusted for baseline values where appropriate.

Baseline and at 12 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Martín Ruiz Ortiz, MD, PhD, Hospital Universitario Reina Sofía. Córdoba. Universidad Internacional Isabel I. Burgos. Spain

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 décembre 2027

Achèvement de l'étude (Estimé)

1 décembre 2027

Dates d'inscription aux études

Première soumission

3 novembre 2026

Première soumission répondant aux critères de contrôle qualité

3 novembre 2026

Première publication (Réel)

9 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data (IPD) that underlie the results reported in future publications (including text, tables, and figures) will be made available to qualified researchers for scientifically sound research proposals. Data sharing will be conducted in strict compliance with the European General Data Protection Regulation (GDPR) and Spanish Organic Law 3/2018. Requests must be evaluated and approved by the competent Research Ethics Committee.

Délai de partage IPD

Available beginning 6 months and ending 5 years following article publication.

Critères d'accès au partage IPD

Data requests should be sent via email to the Principal Investigator (maruor@gmail.com) and the Data Protection Officers (dpo@ui1.es / dpd@imibic.org). Requesters must provide a methodologically sound proposal and obtain prior approval from an authorized Research Ethics Committee. Data will be shared via a secure, encrypted file transfer.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner